Oncology

 

Oncology

Measuring Biomarkers
at Every Stage
of Tumor Development

The ability to detect oncology biomarkers at ultra-low levels has the potential to enable new options for diagnostics and treatment in cancer research.

Simoa assays have the potential to be used to monitor cancer risk, identify early-stage cancers and discriminate between benign and malignant cells. Simoa biomarkers also have the potential to be used prognostically to predict disease outcome, predict progression-free survival and monitor reoccurrence, and to be used to monitor sensitivity to therapy and to aid in treatment decisions.

Latest Publications

Quanterix' digital health solution, Simoa, is changing the way researchers, academics and drug manufacturers measure and detect various forms of cancer at the earliest stage. Quanterix' focus in oncology is growing with a network of academic researchers and pharmaceutical and biotech partners. Learn about Simoa's application in oncology by exploring our scientific publications and journals.

Latest News

08.10
Conference Date: November 7-11, 2018    Booth #326    
05.23
Speaker:  Dan Sikkema, PhD, Vice President Biomarker Services, QuanterixModerator: Dr. Jayshan Carpen, Moderator, Nature Research